Cardia

Cardia is a medical device company specializing in the development, manufacturing, and marketing of state-of-the-art transcatheter septal occluders. These devices are designed to treat congenital cardiac defects, such as Atrial Septal Defects (ASD), by closing the openings in the heart's septum. Cardia's primary clients are healthcare providers, including hospitals and specialized cardiac centers, that require advanced solutions for treating congenital heart conditions. The company operates in the medical device market, focusing on innovative cardiac solutions.

Cardia's business model revolves around the sale of its proprietary medical devices, including the Ultrasept ASD, Ultrasept PFO, Ultrasept LAA, Ultrasept Cribriform, and the Fontan Occluder Delivery System. Revenue is generated through direct sales to healthcare institutions and partnerships with medical distributors. The company's patented self-centering mechanism ensures optimal positioning and repositioning of the devices, making them highly effective and easy to deploy.

Cardia's mission is to improve the quality of life for individuals with congenital heart defects by providing reliable and advanced medical solutions.

Keywords: transcatheter, septal occluders, congenital cardiac defects, ASD, PFO, LAA, Cribriform, Fontan Occluder, self-centering mechanism, healthcare providers.